Is DRMA or DYN more undervalued in 2026?

CirclFi compares Dermata Therapeutics, Inc. (DRMA) and Dyne Therapeutics, Inc. (DYN) using 13 institutional-grade valuation models. DRMA has a Quality of Company score of 2.8/10 while DYN scores 5.0/10.

Which is a better buy — DRMA or DYN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DRMA and DYN valuations compare?

DRMA at $1.30 and DYN at $19.33 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DRMA vs DYN Valuation Comparison 2026 — Intrinsic Value Analysis

DRMA

Pharmaceutical Preparations

Dermata Therapeutics, Inc.

Quality

2.8

out of 10

Value Trap

LOW

Price

$1.30

Last close

Models

7/13

Active

DYN

Pharmaceutical Preparations

Dyne Therapeutics, Inc.

Quality

5.0

out of 10

Value Trap

SAFE

Price

$19.33

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	DRMA Fair Value	DRMA Upside	DYN Fair Value	DYN Upside
Bayesian DCF	Intrinsic	$1.27	-2.2%	$7.29	-62.3%
Earnings Power Value	Intrinsic	—	—	$10.61	-41.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.26	-2.7%	$7.01	-63.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DRMA vs DYN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DRMA vs DYN — Which Stock Is More Undervalued?

DYN scores higher with a 5.0/10 quality rating vs DRMA's 2.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Dermata Therapeutics, Inc. (DRMA) and Dyne Therapeutics, Inc. (DYN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DRMA currently trades at $1.30 with a QOC of 2.8/10, while DYN trades at $19.33 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).